MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding MiNK Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 34 | 31 | −3 |
| Shares | 936.8K | 898.7K | −38.1K (−4.1%) |
| Value | $848.1K | $847.8K | −$278 (0.0%) |
New holders (3)
Institutions that held MiNK Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Camelot Portfolios, LLC | 205 | $195 | 0.00% |
| Clearstead Advisors, LLC | 150 | $143 | 0.00% |
| Assetmark, Inc | 1 | $1 | 0.00% |
Sold out (6)
Institutions that held MiNK Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 29,831 | $27.1K |
| Citadel Advisors LLC | 20,809 | $18.9K |
| Artal Group S.A. | 1,916 | $1.74K |
| Sittner & Nelson, LLC | 58 | $53 |
| Rhumbline Advisers | 48 | $43 |
| LifeSteps Financial, Inc. | 28 | $25 |